T cell antigen receptor vaccines for active therapy of T cell malignancies

Sunil A. Reddy, Craig Okada, Carmen Wong, David Bahler, Ronald Levya

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalAnnals of the New York Academy of Sciences
StatePublished - 2001
Externally publishedYes


  • Idiotype
  • Mycosis fungoides
  • T cell malignancies
  • T cell receptor
  • Tumor antigens
  • Vaccine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'T cell antigen receptor vaccines for active therapy of T cell malignancies'. Together they form a unique fingerprint.

Cite this